Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study

Lonial, Sagar, Lee, Hans C., Badros, Ashraf, Trudel, Suzanne, Nooka, Ajay K., Chari, Ajai, Abdallah, Al‐Ola, Callander, Natalie, Sborov, Douglas, Suvannasankha, Attaya, Weisel, Katja, Voorhees, Peter M., Womersley, Lynsey, Baron, January, Piontek, Trisha, Lewis, Eric, Opalinska, Joanna, Gupta, Ira, Cohen, Adam D.·2021·Cancer
DOI 10.1002/cncr.33809

Cited by (143)

Items 101–143 of 143

  1. BCMA-targeting BiTE molecule AMG 420 in relapsed or refractory multiple myeloma: a phase 1b open-label expansion study
    Cesar Rodriguez, Tulio E. Rodriguez, Alain Kentos, Christoph Driessen, Kazutaka Suanmi, Alexander M. Lesokhin, Andrew Jenho Yee, Alex C. Minella, Ravikanth Maraboina, Vijay V. Upreti et al. · 2025 · Leukemia & lymphoma/Leukemia and lymphoma
  2. Targets Selection for Precision Therapy of Relapsed/Refractory Multiple Myeloma: the Latest Advancements
    Zhen Wang, Yanqi Song, Honglei Guo, Yuting Yan, Lin Ma, Baoshan Liu · 2025 · Current Treatment Options in Oncology
  3. Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on safety and efficacy
    Muhamed Baljević, Gary John Schiller, Tomer Martin Mark, Dane R. Van Domelen, Cristina Gasparetto · 2025 · Frontiers in Oncology
  4. Dose Delays and Treatment Interruptions Secondary to Ocular Toxicity From BCMA-Directed Antibody Drug Conjugate Therapy in Relapsed Multiple Myeloma
    Matthew J. Rees, Timothy T. Xu, Suheil Albert Atallah‐Yunes, Kenneth J C Lim, Sikander Ailawadhi, Ricardo Daniel Parrondo, Rafaël Fonseca, Peter Leif Bergsagel, Suzanne E. Hayman, Angela A. Dispenzieri et al. · 2025 · Clinical Lymphoma Myeloma & Leukemia
  5. Endless possibilities and how to exploit them? What is the optimal treatment sequence?
    Rajshekhar Chakraborty, Divaya Bhutani, Suzanne Lentzsch · 2025 · Hematology. American Society of Hematology. Education Program
  6. Antibody Drug Conjugates in Multiple Myeloma
    Christopher James Ferreri, Hans Chulhee Lee · 2022 · The Cancer Journal
  7. Pathogenesis, clinical characteristics and personalized managements of multiple myeloma with chromosome 1 abnormalities
    Pan Zhou, Weiya Li, Suqiong Zuo, Rongjun Ma, Xiaoli Yuan, Zunmin Zhu · 2023 · Leukemia & lymphoma/Leukemia and lymphoma
  8. Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma
    Rakesh Popat, Sagar Lonial, Peter Michael Voorhees, Simona Degli Esposti, Boris Gorsh, Ira V Gupta, Joanna Opalińska, Sandhya J. Sapra, Trisha Piontek, Zangdong He et al. · 2023 · Journal of the Advanced Practitioner in Oncology
  9. Corneal Toxicity in Patients Treated by BELANTAMAB MAFODOTIN: How to Improve and Facilitate Patients Follow-Up Using Refractive Shift?
    Jason Chauvier, Marie-Caroline Trone, Philippe Gain, Édouard Ollier, Pierre‐Yves Robert, Louis Arnould, Tristan Bourcier, Myriam Cassagne, T. Maalouf, Arnaud Martel et al. · 2024 · Journal of Ocular Pharmacology and Therapeutics
  10. Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma
    Aaron D. Springer, Rengang Wang, Jiawei Wang, Qinyi Du, Willie Pi, Austin Q. Nguyen, Xiaoqing Li, Alisher B. Khasanov, Tong Zhu, Zheng Yan et al. · 2024 · Cancer Research Communications
  11. New Enhancing Oncology Model builds on knowledge from the OCM
    Staggs,Stuart; · 2022 · The American Journal of Managed Care
  12. Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma
    Donna Ellen Reece, Joris Diels, Suzy Van Sanden, Lixia Pei, Eric M. Ammann, Christoph Johann Heuck, Colleen M. Kane, Anil Londhe, Steve Peterson, Ajai Chari · 2024 · Current Medical Research and Opinion
  13. Outcomes in patients with relapsed/refractory multiple myeloma with extramedullary disease: a meta-analysis
    Peter Michael Voorhees, Shaji Kunnathu Kumar, Saad Z. Usmani, Jing Christine Ye, Yael Chava Cohen, Emma Scott, Robin L. Carson, Christoph Johann Heuck, Ryan W. Gan, Benjamin Ackerman et al. · 2025 · Annals of Hematology
  14. Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States
    Anshul Shah, Jonathan C. Tosh, Apoorva Ambavane, Andreas Nikolaou, Cosmina S. Hogea, Yevgeniy Samyshkin, Boris Gorsh, Eric M. Maiese, Feng Wang · 2021 · ClinicoEconomics and Outcomes Research
  15. Recent Updates in the Diagnosis and Management of Kidney Diseases in Multiple Myeloma
    Kenar D. Jhaveri, Priti Meena, Joyita Bharati, Srikanth Bathini · 2024 · Indian Journal of Nephrology
  16. Focal and Segmental Glomerulosclerosis in a Multiple Myeloma Patient After Belantamab Mafodotin Therapy and Severe COVID-19 Infection: A Case Report
    Mohamed Sabbah, Stéphanie Nguyen, Maya Ouzegdouh, Sylvain Choquet, David Buob, J.J. Boffa, Alexandre Cez, Laurent Garderet · 2024 · American Journal of Case Reports
  17. Treatment Patterns, Efficacy, and Tolerability of Belantamab Mafodotin in Patients With Relapsed and/or Refractory Multiple Myeloma: A Real-World Analysis
    Mihir N. Patel, Susan C. Locke, Caroline A. Falvey, Jesse D. Troy, Kris W. Herring, Amanda Florence Bolgioni, Cherie Howard Elcock, Laura L. Iadeluca, Cristiana Costa Chase, Cristina Gasparetto et al. · 2025 · Clinical Lymphoma Myeloma & Leukemia
  18. Embracing Myeloma Chimeric Antigen Receptor-T: From Scientific Design to Clinical Impact
    Hitomi Hosoya, Paula Rodríguez‐Otero, Surbhi Sidana, Ivan Borrello · 2023 · American Society of Clinical Oncology Educational Book
  19. ZNF655 involved in the progression of multiple myeloma via the activation of AKT
    Haiming Kou, Shuqin Jiang, Xueqiong Wu, Changhua Jing, Xinxin Xu, Jiaju Wang, Cui Zhang, Wenting Liu, Yan Qing Gao, Qian Men et al. · 2024 · Cell Biology International
  20. Addressing cancer health disparities in a multilateral collaboration in an independent community cancer clinic: translating words into action
    Kashyap Patel, MD;Mukhi,Hirangi;Patel,Anjana;Nathwani,Niyanti;Mehta,Dhwani;Sherak,Jennifer;Clinton,Natasha ;Pisarik,Holly ;Brown,Benjamin ;Rogers,Sara;Mary Kruczynski;Ferreyros,Nicolas ;Ted Okon, MBA; · 2022 · The American Journal of Managed Care
  21. Management of relapsed multiple myeloma: A British Society of Haematology and UK Myeloma Society guideline
    Matthew W. Jenner, Kevin D. Boyd, Satarupa Choudhuri, Christopher Parrish, Mamta Krishnan Garg, Simon Stern, the British Society of Haematology and UK Myeloma Society · 2025 · British Journal of Haematology
  22. Onkologika
    Wolf-Dieter Ludwig, Arnold Ganser, Georg Maschmeyer · 2021 · Springer eBooks
  23. Treatment with low‐dose, single‐agent belantamab mafodotin is safe and provides long‐term responses in heavily pretreated multiple myeloma patients
    Irit Mazza Avivi, Tamir Shragai, Efrat Luttwak, Svetlana Trestman, Yael Chava Cohen · 2023 · European Journal Of Haematology
  24. Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti‐CD38 Monoclonal Antibodies: A Systematic Review
    Chia Jie Tan, Dylan Kacerek, Nattawara Kampirapawong, Amandeep Godara, Nathorn Chaiyakunapruk · 2025 · Cancer Medicine
  25. An update on novel multiple myeloma targets
    Massimo Offidani, Laura Corvatta, Sonia Morè, Valentina Maria Manieri, Attilio Olivieri · 2022 · Expert Review of Hematology
  26. Microinquinanti organici in Provincia di Venezia Livelli in aria ambiente ed emissioni in atmosfera
    Via Lissa · 2009
  27. Deciding Which Cancer-Related Fatigue Assessment Tool to Use Just Got Much Easier
    Lisa K. Sprod · 2022 · ONCOLOGY
  28. Making Progress in PTCL: Significant Unmet Needs
    Nasta,Sunita; · 2022 · ONCOLOGY
  29. A Focus on Special Populations in Relapsed Multiple Myeloma
    Mary Nicole Steinbach, Kathleen Colson, Beth M Faiman · 2022 · Journal of the Advanced Practitioner in Oncology
  30. A call to action: oncology practices—and patients—need performance measures for managing oral therapies
    Natasha Khrystolubova · 2022 · The American Journal of Managed Care
  31. Updates on Multiple Myeloma: What’s New in Risk Stratification, Treatment, and Prognosis
    Enas Yahya Mutahar · 2022 · IntechOpen eBooks
  32. Two to Tango: CD3/BCMA Bispecific Antibodies in Multiple Myeloma
    Sham Mailankody, Saad Z. Usmani · 2022 · The Hematologist
  33. Hämatologische Neoplasien und solide Tumore
    Wolf-Dieter Ludwig, Arnold Ganser, Georg Maschmeyer · 2022 · Springer eBooks
  34. An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma
    Paula Rodríguez‐Otero, Kevin M. Towle, Shannon F. Cope, Clyde Caisip, Faith E. Davies, Michel Delforge, Katja Christina Weisel, Thomas S. Marshall, Korinna Karampampa, Dieter Ayers et al. · 2023 · Leukemia & lymphoma/Leukemia and lymphoma
  35. The Gaining Momentum of BCMA-Directed Therapies for Relapsed/Refractory Multiple Myeloma
    Adrian Schmidt · 2023 · healthbook TIMES Oncology Hematology
  36. Belantamab-mafodotin-associated keratopathy
    Zaynab Khattabi, Vadim Lesan, T. Berger, Berthold Seitz, L. Hamon · 2024 · Journal Français d Ophtalmologie
  37. Novel Healthcare Trends
    Pragya Karnwal, Madhav Chaudhary, Shweta Bajaj, Rajesh Tiwari · 2025 · IGI Global eBooks
  38. Belantamab mafodotin for the treatment of multiple myeloma
    Albert Oriol, Gladys Ibarra, Jordi Loscos, Laura Abril · 2025 · Expert Opinion on Biological Therapy
  39. A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM)
    Yuxin Liu, Ji Hyun Lee, Clifton Craig Mo, Taya Jamal Salman, Shahrier Hossain, Shonali Midha, Omar Nadeem, Taylor Nicholson, Jessica Croteau, Natalie Kazierad et al. · 2026 · Expert Opinion on Biological Therapy
  40. Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management
    Roberto Mina, Evangelos Terpos, Lorenzo Cani, Ajay K. Nooka, Suzanne Trudel, Peeter Voorhees, Hira S. Mian, Binod Dhakal, Saad Z. Usmani, Joshua Richter et al. · 2026 · Clinical Lymphoma Myeloma & Leukemia
  41. When Myeloma Escapes the Bone Marrow: Extramedullary Disease in the Immunotherapy Era
    Aimaz Afrough, Christen M. Dillard, Anne M. Alsup, Jimmy Lee, Samer al Hadidi, Aishwarya Sannareddy, P. Abraham, Laura Turer, Danai Dima, A. Khan et al. · 2026 · Cancers
  42. Monoclonal Antibodies and Antibody-Drug Conjugates
    Ioannis Ntanasis‐Stathopoulos, Evangelos Terpos, Meletios Athanasios Dimopoulos · 2026 · The Cancer Journal
  43. BCMA ‐Targeted Immunotherapy in Early Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Practical Management
    Massimo Vincenzo Martino, Erica Bilardi, Martina Pitea, Gaetana Porto, Giorgia Policastro, Giovanna Utano, Laura Giordano, Giulia Santoro, Jessyca Germanò, Caterina Alati · 2026 · European Journal Of Haematology